PTC Therapeutics (PTCT): Navigating Regulatory Waters In Europe
In a recent development, the European Commission has chosen not to adopt the negative opinion put forth by the Committee for Medicinal Products for Human Use (CHMP) regarding the annual renewal of the conditional marketing authorization of Translarna (ataluren), a protein restoration therapy developed by PTC Therapeutics, Inc. This decision has had a significant impact […]
